SMG-SNU Boramae Medical Center at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

SMG-SNU Boramae Medical Center takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on markers of disease and treatment response. Its work covers blood pressure reactivity during lecanemab infusion and the ordering of plasma and PET biomarkers along disease progression.

Organization	CTAD 2026 Attendance
SB SMG-SNU Boramae Medical Center Seoul, South Korea
	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Peri-infusion Blood Pressure Reactivity as a Non-Invasive Marker of Cerebrovascular Amyloid Burden during Lecanemab Treatment in Early Alzheimer’s Disease (P150) Anti-amyloid and anti-tau therapies Poster Wed Nov 18 7:15am–5:30pm Inflection-based ordering of plasma and PET biomarkers along an Alzheimer’s disease progression axis in two independent cohorts (P266) Blood and CSF biomarkers · PET and MRI imaging

Organization

CTAD 2026 Attendance

SMG-SNU Boramae Medical Center

Seoul, South Korea

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Peri-infusion Blood Pressure Reactivity as a Non-Invasive Marker of Cerebrovascular Amyloid Burden during Lecanemab Treatment in Early Alzheimer’s Disease (P150)

Anti-amyloid and anti-tau therapies

Poster

Wed Nov 18
7:15am–5:30pm

Inflection-based ordering of plasma and PET biomarkers along an Alzheimer’s disease progression axis in two independent cohorts (P266)

Blood and CSF biomarkers · PET and MRI imaging

Instantly find 20 buyers from SMG-SNU Boramae Medical Center

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction